

GENELABS TECHNOLOGIES INC /CA  
Form SC TO-T/A  
November 21, 2008

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Schedule TO**  
**Amendment No. 1**  
**(Rule 14d-100)**

**Tender Offer Statement under Section 14(d)(1) or 13(e)(1)**  
**of the Securities Exchange Act of 1934**

**GENELABS TECHNOLOGIES, INC.**  
*(Name of Subject Company (Issuer))*  
**Gemstone Acquisition Corporation**  
**and**  
**GlaxoSmithKline plc**  
*(Names of Filing Persons (Offerors))*

**Common Stock, no par value per share**  
*(Title of Class of Securities)*

**368706206**  
*(CUSIP Number of Class of Securities)*

**Carol G. Ashe, Esq.**  
**GlaxoSmithKline**  
**One Franklin Plaza (FP 2355)**  
**200 N. 16th Street**  
**Philadelphia, Pennsylvania 19102**  
**(215) 741-4000**

*(Name, Address and Telephone Numbers of Person Authorized  
to Receive Notices and Communications on Behalf of Filing Persons)*

**Copy to:**

**Benet J. O Reilly, Esq.**  
**Cleary Gottlieb Steen & Hamilton LLP**  
**One Liberty Plaza**  
**New York, New York 10006**  
**(212) 225-2000**

**CALCULATION OF FILING FEE**

	<b>Amount of Filing Fee**</b>
<b>Transaction Valuation*</b>	
<b>\$57,107,614.50</b>	<b>\$ 2,244.33</b>

\* For purposes of  
calculating the

filing fee pursuant to Rule 0-11(d) only, the transaction valuation was calculated by adding the sum of (a) the offer price of \$1.30 per share of common stock, no par value per share, of Genelabs Technologies, Inc. (the Shares ) multiplied by 43,684,465 shares of common stock issued and outstanding, and (b) the offer price of \$1.30 minus \$0.69, which is the weighted average exercise price of outstanding in-the-money options to acquire Shares multiplied by 521,000, the number of outstanding in-the-money options.

\*\* The filing fee, calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, is calculated by multiplying the Transaction

Valuation by  
.00003930.

- Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: **\$2,244.33**

Filing Party: **Gemstone Acquisition Corporation  
and**

**GlaxoSmithKline plc**

Form or Registration No.: **Schedule TO**

Date Filed: **November 12, 2008**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

third-party tender offer subject to Rule 14d-1.

issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

---

This Amendment No. 1 to the Tender Offer Statement on Schedule TO (this Amendment), filed with the Securities and Exchange Commission on November 20, 2008, amends and supplements the Tender Offer Statement on Schedule TO filed on November 12, 2008 (the Schedule TO) and relates to the offer by Gemstone Acquisition Corporation, a California corporation ( Purchaser ) and a wholly-owned subsidiary of SmithKline Beecham Corporation, a Pennsylvania corporation ( SKB ) and a wholly-owned subsidiary of GlaxoSmithKline plc, a public limited company organized under the laws of England and Wales ( GSK ), to purchase all outstanding shares of common stock, no par value per share (the Shares), of Genelabs Technologies, Inc., a California corporation ( Genelabs ), at a price of \$1.30 per Share, net to the seller in cash, without interest thereon and less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 12, 2008 (the Offer to Purchase) and in the related Letter of Transmittal (which, together with any amendments or supplements thereto, collectively constitute the Offer), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. This Amendment is being filed on behalf of Purchaser and GSK.

All information set forth in the Offer to Purchase filed as Exhibit (a)(1)(A) to the Schedule TO is incorporated by reference in answer to Items 1 through 11 in the Schedule TO, except those items as to which information is specifically provided herein. The Agreement and Plan of Merger, dated as of October 29, 2008, by and among Purchaser, SKB and Genelabs, a copy of which is attached as Exhibit (d)(1) to the Schedule TO, is incorporated herein by reference with respect to Items 4 through 11 of the Schedule TO.

**Item 11. Additional Information.**

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following:

The putative shareholder class action initiated on November 4, 2008, by Lanre Rotimi Rollover IRA against Genelabs, members of the Genelabs Board of Directors and GSK in the Superior Court of California, County of San Mateo was removed to the United States District Court Northern District of California, San Francisco Division on November 12, 2008.

---

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GlaxoSmithKline plc

By: /s/ Simon M. Bicknell  
Name: Simon M. Bicknell  
Title: Secretary

Gemstone Acquisition Corporation

By: /s/ Carol G. Ashe  
Name: Carol G. Ashe  
Title: Authorized Signatory

Dated: November 20, 2008